Publications by authors named "E W Humke"
The efficient transport of proteins into the primary cilium is a crucial step for many signaling pathways. Dysfunction of this process can lead to the disruption of signaling cascades or cilium assembly, resulting in developmental disorders and cancer. Previous studies on the protein delivery to the cilium were mostly focused on the membrane-embedded receptors.
View Article and Find Full Text PDFArticle Synopsis
- GDC-0927 is a new oral medication designed to target and degrade estrogen receptors, showing potential in treating ER+ breast cancer by inducing tumor regression in lab models.
- In a phase I study involving postmenopausal women with metastatic breast cancer, the drug was found to be safe, with common side effects including nausea and fatigue, but no severe adverse events or deaths reported.
- Although no complete or partial tumor responses were observed, about 29% of patients experienced clinical benefits, with significant reductions in estrogen receptor activity that suggest the drug successfully engages its target.
Death receptor 5 (DR5) is an attractive target for cancer therapy due to its broad upregulated expression in multiple cancers and ability to directly induce apoptosis. Though anti-DR5 IgG antibodies have been evaluated in clinical trials, limited efficacy has been attributed to insufficient receptor crosslinking. IGM-8444 is an engineered, multivalent agonistic IgM antibody with 10 binding sites to DR5 that induces cancer cell apoptosis through efficient DR5 multimerization.
View Article and Find Full Text PDFObjectives: MUC16 is overexpressed in the majority of human epithelial ovarian cancers (OC). DMUC4064A is a humanized anti-MUC16 monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E. This trial assessed the safety, tolerability, pharmacokinetics, and preliminary activity of DMUC4064A in patients with platinum-resistant OC.
View Article and Find Full Text PDFObjective: This study investigated the safety and tolerability of lifastuzumab vedotin (DNIB0600A) (LIFA), an antibody-drug conjugate, in patients with recurrent platinum-sensitive ovarian cancer (PSOC).
Methods: In this open-label, multicenter phase 1b study, LIFA was administered intravenously once every 3 weeks (Q3W) with starting dose 1.2 mg/kg in a 3 + 3 dose-escalation scheme.